Scientists Eliminated ‘Zombie’ Gut Cells in Mice, Curing Their Colitis

Researchers studying colitis in mice just demonstrated something that sounds like science fiction: they genetically wiped out a population of aging "zombie" cells lining the gut, and the inflammation driving the disease largely resolved. Then, in a separate experiment, they found a specific probiotic strain could produce a strikingly similar effect just by reshaping the gut's bacterial community. The same aging-cell signature the researchers targeted also showed up in tissue from human patients with inflammatory bowel disease (IBD).

Key takeaways:

• In mice with chemically induced colitis, genetically eliminating "senescent" cells (aging cells that stop dividing but refuse to die, sometimes called zombie cells) reduced colon damage, inflammation, and a cell-stress signaling pathway called STAT3.
• A specific probiotic strain, Lacticaseibacillus rhamnosus Probio-M9, produced comparable improvements in colitis severity by reshaping the mix of gut bacteria, without directly killing the senescent cells.
• The same senescent-cell signature (marked by a protein called p16) was found in human IBD tissue and tracked with disease severity and response to a common IBD drug across five independent public datasets, adding real-world weight to the mouse findings.

Eliminating 'Zombie' Cells Reversed Colitis In Mice

The study, published in the journal Engineering by a joint China-Japan research team, focused on cellular senescence (a state where damaged or stressed cells stop dividing and linger indefinitely instead of dying, dumping a steady stream of inflammatory molecules into surrounding tissue, called the senescence-associated secretory phenotype, or SASP). Using a genetically engineered mouse model, the researchers could selectively label and then trigger the destruction of p16-positive senescent cells (identified by a common aging marker) in mice with dextran sulfate sodium (DSS)-induced colitis, a standard way scientists chemically trigger ulcerative-colitis-like inflammation in the lab. Once those senescent cells were eliminated, the mice showed reduced disease-activity scores, less colon shortening, and a drop in inflammatory cytokines and the SASP markers MCP1 and IP-10, alongside restored gut-lining repair. This adds to a broader review of senescent cells in IBD, which has increasingly identified senescent-cell buildup as a driver, not just a bystander, of chronic gut inflammation.

Why This Matters For People Managing IBD

For the roughly several million people worldwide living with Crohn's disease or ulcerative colitis, current treatment options remain limited, and this line of research points toward a mechanism, cellular aging inside the gut, that current drugs largely don't target. The study's human validation work is the part most relevant to readers researching their own IBD: senescence-associated gene signatures were elevated in inflamed colon tissue from IBD patients compared to non-inflamed tissue, tracked with more severe endoscopic disease activity, and were higher in people who didn't respond well to infliximab, a widely used anti-inflammatory IBD drug. That last finding hints that measuring senescence markers could eventually help predict which patients will respond to which treatments, though that application hasn't been tested prospectively.

How The Researchers Tested Cause And Effect, Not Just Correlation

What sets this study apart from a simple observational finding is that the researchers tested causation directly. They used two complementary mouse models: one that let them label and track senescent cells with a fluorescent marker, and a second, more powerful model that let them selectively kill off only the p16-positive senescent cells (using a targeted toxin system) after the mice already had colitis. Removing those cells specifically improved colitis, evidence the senescent cells weren't just markers of a damaged colon but active drivers of continued inflammation. Separately, they gave a third group of DSS-colitis mice daily oral doses of the probiotic Probio-M9 and ran metagenomic sequencing on their stool to track how the gut bacterial community changed over a 49-day intervention. To check whether the mouse findings held up in real patients, the team then analyzed human colon biopsy tissue directly and cross-referenced five independent public gene-expression datasets covering hundreds of IBD patients, plus a single-cell dataset that pinpointed which gut cell types carry the senescence signature (predominantly inflammatory immune cells called myeloid cells).

A Common Probiotic Strain Reshaped Gut Bacteria And Eased Inflammation Too

The probiotic-treated mice didn't show the same drop in the core senescence markers p21 and p53 that the direct cell-elimination experiment did, which led the researchers to conclude Probio-M9 isn't acting as a direct "senolytic" (a compound that kills senescent cells outright). Instead, they propose it works upstream, by altering gut bacterial composition and the metabolic byproducts those bacteria produce, in turn reducing the inflammatory and metabolic stress that generates new senescent cells in the first place. This fits with prior work on the same probiotic strain: a placebo-controlled human trial of the same probiotic strain already found Probio-M9 supplementation reliably shifts gut microbial diversity in healthy adults, though that trial measured stress and quality-of-life outcomes, not colitis or senescence markers directly. It's worth being explicit here: this study does not establish that Probio-M9, or any probiotic, is a proven treatment for human IBD; it shows a mechanistic parallel in a mouse model that researchers now want to test more directly.

What Remains Unproven

This is a mouse study; the DSS colitis model mimics some features of human ulcerative colitis but is a chemically induced model, not the real disease, and results don't automatically translate to people. The researchers acknowledge several limitations: the microbial metabolic pathway changes they identified were inferred from genetic sequencing data rather than confirmed with direct metabolite measurements, and the entire mouse study was conducted exclusively in female mice, with verification in males still pending. A 2026 review on senescence in Crohn's disease similarly notes that senescence plays a complex, sometimes contradictory role in gut disease, underscoring that this remains an active, unsettled area of research rather than a solved problem. The authors reported no competing financial interests, and the work was funded by Japanese and Chinese public science agencies, not a probiotic manufacturer.

What Comes Next

The authors call for follow-up work to directly measure the gut metabolites (short-chain fatty acids, tryptophan-derived compounds) they believe link the probiotic-driven microbiome shift to reduced cellular senescence, verification of the findings in male mice, and further work to pin down exactly which gut cell types are being regulated by microbiota-derived signals. No human clinical trial of Probio-M9 for IBD has been announced.

Common Questions

Can I take a Probio-M9 probiotic supplement to treat colitis? This study does not test or establish that in humans; it shows a mechanistic effect in a mouse colitis model, and any use of probiotics for an existing IBD diagnosis should be discussed with a gastroenterologist rather than self-directed based on this research.

What are "senescent" or "zombie" cells? They're cells that have stopped dividing due to damage or stress but don't die off as they normally would, and instead persist while releasing inflammatory signaling molecules into surrounding tissue, a process called the senescence-associated secretory phenotype, or SASP.

Does this mean senescent cells cause IBD in humans, not just mice? The mouse experiments show senescent cells actively drive inflammation when researchers manipulate them directly, and the human tissue and dataset analysis found the same senescence signature is elevated in IBD patients and tracks with disease severity, but a causal role in humans specifically has not been directly tested.

Is the probiotic doing the same thing as directly killing the senescent cells? Not exactly. The genetic cell-elimination experiment reduced senescence markers directly, while Probio-M9 treatment improved colitis without changing the core senescence markers p21 and p53, suggesting it works indirectly by reshaping gut bacteria and reducing the inflammatory pressure that generates new senescent cells.

References

1. Gaopeng Li, Zhixin Zhao, Feiyan Zhao, et al. (2026). Probio-M9 and Genetic Senolysis Attenuate Experimental Colitis by Targeting Inflammation-Associated Cellular Senescence. Engineering. https://doi.org/10.1016/j.eng.2026.07.037
2. Lichao Yang, Lianwen Yuan (2025). The role and intrinsic connection of cellular senescence and cell death in inflammatory bowel disease. Frontiers in Cell and Developmental Biology. https://doi.org/10.3389/fcell.2025.1502531
3. Yan Zheng, Zhongjie Yu, Wenyi Zhang, Tiansong Sun (2021). Lactobacillus rhamnosus Probio-M9 Improves the Quality of Life in Stressed Adults by Gut Microbiota. Foods. https://doi.org/10.3390/foods10102384
4. Jinguo Liu, Liangliang Yu (2026). Cellular senescence in Crohn’s disease: a double-edged sword in intestinal fibrosis. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1825690